Основная статистика
| CIK | 1830214 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Soaring Eagle Acquisition Corp - Units (1 Ord Share Class A & 1/5 War)
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 4, 2025 |
Exhibit 1.1 Ginkgo Bioworks Holdings, Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement September 4, 2025 Allen & Company LLC 711 Fifth Avenue New York, NY 10022 To the addressee set forth above: Ginkgo Bioworks Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Allen & Company LLC (the |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (C |
|
| September 4, 2025 |
GINKGO BIOWORKS HOLDINGS, INC. Class A Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-289390 PROSPECTUS SUPPLEMENT (To Prospectus dated August 14, 2025) GINKGO BIOWORKS HOLDINGS, INC. $100,000,000 Class A Common Stock We have entered into a sales agreement (the “Sales Agreement”) with Allen & Company LLC (“Allen” or the “agent”), relating to the sale of up to $100,000,000 of shares of Class A common stock |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 7, 2025 |
Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2025 Financial Results Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Mass – August 7, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the second |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2025 |
Calculation of Filing Fee Tables S-3 Ginkgo Bioworks Holdings, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
Ginkgo Bioworks Holdings, Inc. Amended and Restated Non-Employee Director Compensation Program Exhibit 10.2 GINKGO BIOWORKS HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended and Restated June 12, 2025 (the “Effective Date”)) Non-employee members of the board of directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), subject to the |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| August 7, 2025 |
Compensation Adjustment Letter dated May 30, 2025, between Ginkgo Bioworks, Inc. and Steven Coen Exhibit 10.1 May 30, 2025 Steven Coen Needham, MA Subject: Compensation Adjustment - Change in Role to Chief Financial Officer Dear Steven, We (“Ginkgo”) are pleased to formally acknowledge your transition from the position of Chief Accounting Officer to Chief Financial Officer (“CFO”), effective May 30, 2025. This change reflects your outstanding performance, leadership, and the confidence we have in your |
|
| June 13, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commis |
|
| May 21, 2025 |
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer Exhibit 99.1 Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer BOSTON, Mass. May 21, 2025 – Ginkgo Bioworks (NYSE: DNA, “Ginkgo” or the “Company”), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company’s Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accep |
|
| May 6, 2025 |
Exhibit 10.1 GINKGO BIOWORKS HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of Ginkgo Bioworks Holdings, Inc. (the “Company”). The Company has granted to th |
|
| May 6, 2025 |
Exhibit 10.2 GINKGO BIOWORKS HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of Ginkgo Bioworks Holdings, Inc. (the “Comp |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| May 6, 2025 |
EX-99.1 2 ex991earningspr.htm EX-99.1 Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2025 Financial Results Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BO |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 25, 2025 |
Description of Securities of the Registrant Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary of the material terms of the capital stock of Ginkgo Bioworks Holdings, Inc. (“Ginkgo,” “we,” “us” and “our”) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our certificate of incorporation (as amended, the “Charter”), our amended and restated bylaws (the “Byl |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| February 25, 2025 |
Exhibit 99.1 Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON, Mass – |
|
| February 25, 2025 |
Ginkgo Bioworks, Inc. 2008 Stock Incentive Plan, as amended as of June 18, 2014 GINKGO BIOWORKS, INC. 2008 STOCK INCENTIVE PLAN AS AMENDED AS OF JUNE 18, 2014 1. Purpose. The purpose of this plan (the “Plan”) is to secure for Ginkgo BioWorks, Inc., a Delaware corporation (the “Company”), and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corpo |
|
| February 25, 2025 |
Form of Ginkgo Bioworks Holdings, Inc. 2021 Employee Stock Purchase Plan GINKGO BIOWORKS HOLDINGS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to qualify |
|
| February 25, 2025 |
Insider Trading Compliance Policy GINKGO BIOWORKS HOLDINGS, INC. INSIDER TRADING COMPLIANCE POLICY (As of August 2, 2024) This Insider Trading Compliance Policy (this “Policy”) consists of six sections: •Section 1 provides an overview; •Section 2 sets forth Ginkgo’s policies prohibiting insider trading; •Section 3 explains insider trading terms; •Section 4 consists of procedures that have been put in place by Ginkgo to prevent ins |
|
| February 25, 2025 |
Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective March 15, 2021 AMENDMENT TO THE GINKGO BIOWORKS, INC. 2014 STOCK INCENTIVE PLAN Effective March 15, 2021 This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the “Plan”) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the “Company”), on March 15, 2021 and approved by th |
|
| February 25, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Legal Name of Subsidiary Jurisdiction of Incorporation or Organization Ginkgo Bioworks, Inc. Delaware Ginkgo Bioworks Securities Corporation Massachusetts Ginkgo Biosecurity, LLC Delaware Ginkgo International Holdings, Inc. Delaware Concentric Consultancy QFZ LLC Qatar |
|
| February 25, 2025 |
GINKGO BIOWORKS HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILITY S |
|
| February 25, 2025 |
Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective May 1, 2019 AMENDMENT TO THE GINKGO BIOWORKS, INC. 2014 STOCK INCENTIVE PLAN Effective May 1, 2019 This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the “Plan”) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the “Company”), on April 8, 2019 and approved by the ho |
|
| February 25, 2025 |
Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective September 9, 2019 Plan Amendment AMENDMENT TO THE GINKGO BIOWORKS, INC. 2014 STOCK INCENTIVE PLAN Effective September 9, 2019 This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the “Plan”) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the “Company”), on September 9, 20 |
|
| February 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2025 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (C |
|
| February 25, 2025 |
As filed with the United States Securities and Exchange Commission on February 25, 2025. S-8 1 ginkgo-sx82025evergreen.htm S-8 As filed with the United States Securities and Exchange Commission on February 25, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-2652913 (State o |
|
| February 25, 2025 |
EX-FILING FEES 2 ginkgo-sx8filingfeetable20.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ginkgo Bioworks Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Pr |
|
| February 25, 2025 |
Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective April 8, 2020 Plan Amendment AMENDMENT TO THE GINKGO BIOWORKS, INC. 2014 STOCK INCENTIVE PLAN Effective April 8, 2020 This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the “Plan”) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the “Company”), on April 8, 2020 and a |
|
| November 14, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securitie |
|
| November 12, 2024 |
Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2024 Financial Results Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON, Mass – November 12, 2024 – Ginkgo Bioworks Holdings, Inc. ( |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| September 12, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange ("NYSE" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Warrants, each Warrant exercisable for one-fortieth (1/40) of one share of the Company's Class A common stock, par value $0. |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (C |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 19, 2024 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GINKGO BIOWORKS HOLDINGS, INC. |
|
| August 15, 2024 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of inc |
|
| August 8, 2024 |
Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2024 Financial Results Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON, Mass – August 8, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its re |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 28, 2024 |
June 28, 2024 By EDGAR Submission Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attn: Lynn Dicker Eric Atallah Division of Corporation Finance, Office of Life Sciences Re: GINKGO BIOWORKS HOLDINGS, INC. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-40097 Dear Ms. Dicker and Mr. Atallah, Ginkgo Bioworks Holdings, Inc. (the “Company”) is submitting th |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 24, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of inc |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| June 13, 2024 |
June 13, 2024 By EDGAR Submission Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attn: Lynn Dicker Eric Atallah Division of Corporation Finance, Office of Life Sciences Re: GINKGO BIOWORKS HOLDINGS, INC. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-40097 Dear Ms. Dicker and Mr. Atallah, Ginkgo Bioworks Holdings, Inc. (the “Company”) is submitting th |
|
| May 17, 2024 |
GINKGO BIOWORKS HOLDINGS, INC. 18,857,026 Shares of Class A common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279280 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. 18,857,026 Shares of Class A common stock This prospectus relates to the resale or other disposition from time to time of up to 18,857,026 shares in the aggregate of Class A common stock, par value $0.0001 per share (the “Class A common stock”), of Ginkgo Bioworks Holdings, Inc., a Delaware corpo |
|
| May 15, 2024 |
Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 May 15, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Ginkgo Bioworks Holdings, Inc. Registration Statement on Form S-3 (File No. 333-279280) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of the |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commiss |
|
| May 13, 2024 |
Exhibit 99.1 Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE Ginkgo’s Class A Common Stock continues to trade on the NYSE BOSTON, Mass – May 13, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo” or the “Company”), which is building the leading platform for cell programming and biosecurity, today announced that it received a notice on May 7, 2024 from the New York Stoc |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
GINKGO BIOWORKS HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of Ginkgo Bioworks Holdings, Inc. (the “Company”). The Company has granted to the participant listed below (“Pa |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2024 |
Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2024 Financial Results Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON, Mass – May 9, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| March 14, 2024 |
Securities and Exchange Commission, dated March Exhibit 16.1 March 14, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated March 14, 2024, of Ginkgo Bioworks Holdings, Inc. and are in agreement with the statements contained in the second and third sentences of the first paragraph and the second and third paragraphs on page 1 therein. We have no basis to agree or |
|
| March 1, 2024 |
As filed with the United States Securities and Exchange Commission on February 29, 2024. As filed with the United States Securities and Exchange Commission on February 29, 2024. |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| February 29, 2024 |
Exhibit 99.1 Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results $251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma Year-end cash balance of nearly $950 million provides meaningful multi-year run |
|
| February 29, 2024 |
Policy for Recoupment of Incentive Compensation GINKGO BIOWORKS HOLDINGS, INC. POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1.Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) has adopted this policy (the “Policy”) providing for the Company’s recoupment of certain incentive-based |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| February 29, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Legal Name of Subsidiary Jurisdiction of Incorporation or Organization Ginkgo Bioworks, Inc. Delaware Ginkgo Bioworks Securities Corporation Massachusetts Concentric by Ginkgo, LLC Delaware Ginkgo International Holdings, Inc. Delaware Concentric Consultancy QFZ LLC Qatar |
|
| February 29, 2024 |
Exhibit 10.31 27 Drydock Avenue Boston, Massachusetts (the “Building”) FIFTEENTH AMENDMENT (“FIFTEENTH AMENDMENT”) Execution Date: August 9, 2023 LANDLORD: BCP-CG 27 Property LLC, a Delaware limited liability company TENANT: Ginkgo Bioworks, Inc., a Delaware corporation EXISTING PREMISES: A total of 196,331 rentable square feet of the Building, as more specifically set forth in the Lease. DATE OF |
|
| February 29, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary of the material terms of the capital stock of Ginkgo Bioworks Holdings, Inc. (“Ginkgo,” “we,” “us” and “our”) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our certificate of incorporation (as amended, the “Charter”), our amended and restated bylaws (the “Byl |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 29, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / Shetty Reshma P. - SC 13D/A Activist Investment SC 13D/A 1 reshma-13d21324.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CUSIP Number) c/o Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue, 8th Floor Boston, MA 02210 (877) 42 |
|
| February 14, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / Kelly Jason R - SC 13D/A Activist Investment SC 13D/A 1 jason-13d21324.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CUSIP Number) c/o Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue, 8th Floor Boston, MA 02210 (877) 422 |
|
| February 14, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / Che Austin - SC 13G/A Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CU |
|
| February 14, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402141013ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A common stock, $0.0001 par value per sh |
|
| February 14, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / Knight Thomas F. Jr. - SC 13G/A Passive Investment SC 13G/A 1 tomknight-13gxa.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Tit |
|
| February 13, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01019-ginkgobioworksholdin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Ginkgo Bioworks Holdings, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 37611X100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the app |
|
| January 29, 2024 |
DNA / Ginkgo Bioworks Holdings, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 10, 2024 |
Exhibit 99.1 Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business Strong growth among blue chip pharma and biotech (“biopharma”) custome |
|
| January 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2023 |
Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2023 Financial Results Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023 Entered into strategic cloud and AI partnership with Google Cloud; first milestone recently achieved Signed new multi-target RNA drug discovery collaboration with Pfizer in which Ginkgo is eligible to receive research fees and development and commercial mil |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| October 27, 2023 |
Exhibit 3.1 Bylaws of Ginkgo Bioworks Holdings, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 3 1.1 Registered Office 3 1.2 Other Offices 3 Article II - Meetings of Stockholders 3 2.1 Place of Meetings 3 2.2 Annual Meeting 3 2.3 Special Meeting 3 2.4 Notice of Business to Be Brought before a Meeting 3 2.5 Notice of Nominations for Election to the Board of Direc |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2023 |
GINKGO BIOWORKS HOLDINGS, INC. 5,283,679 Shares of Class A common stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274171 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. 5,283,679 Shares of Class A common stock This prospectus relates to the resale or other disposition from time to time of up to 5,283,679 shares in the aggregate (the “Shares”) of Class A common stock, par value $0.0001 per share (the “Class A common stock”), of Ginkgo Bioworks H |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2023 |
Exhibit 99.1 Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity • Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership • Ginkgo to pioneer new large language models for biological engineering applications, powered by Google Cloud's Vertex AI platform • Ginkgo intends to make Google its primary cloud service |
|
| August 25, 2023 |
Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 August 25, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Ginkgo Bioworks Holdings, Inc. Registration Statement on Form S-3 (File No. 333-274171) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of |
|
| August 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| August 23, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 23, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 23, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial information and related notes have been prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 gives effect to the Merger (as defined below) as |
|
| August 23, 2023 |
As filed with the Securities and Exchange Commission on August 23, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 23, 2023 Registration No. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| August 9, 2023 |
Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2023 Financial Results Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023 Highlighted continued success selling into large established biotech R&D organizations with recently expanded relationships with Sumitomo, Novo Nordisk, and Merck Ginkgo ended Q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| May 10, 2023 |
Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2023 Financial Results Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023 Recent acquisition of the adeno-associated virus (AAV) capsid engineering platform assets of StrideBio is advancing Ginkgo’s capabilities and commercial potential in gene therapy Ginkgo ended Q1 2023 with approximately $1.2 billion in cash and cash equivale |
|
| May 5, 2023 |
Exhibit 99.1 Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer Mr. Coen brings over 30 years of public accounting and corporate finance leadership experience, most recently as Corporate Vice President and Corporate Controller at Charles River Laboratories Marie Fallon to step down as CAO effective May 15, 2023 BOSTON, MA - May 5, 2023 - Ginkgo Bioworks Holdings, I |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commiss |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 13, 2023 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary of the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Charter, our Bylaws and the Warrant-related documents described herein, which are filed with the Securities and Exchange Commission (the “SEC”). We urge you to read e |
|
| March 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| March 13, 2023 |
As filed with the United States Securities and Exchange Commission on March 13, 2023. As filed with the United States Securities and Exchange Commission on March 13, 2023. |
|
| March 13, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Legal Name of Subsidiary Jurisdiction of Incorporation or Organization Ginkgo Bioworks, Inc. Delaware Ginkgo Bioworks Securities Corporation Massachusetts Concentric by Ginkgo, LLC Delaware Zymergen Inc. Delaware |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Comm |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| March 1, 2023 |
Exhibit 99.1 Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance Year end cash balance of over $1.3 billion provides meaningful multi-year runway as we d |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| February 14, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / Che Austin - SC 13G/A Passive Investment SC 13G/A CUSIP No. 37611X100 Schedule 13G Page 1 of 5 Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Com |
|
| February 14, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / Knight Thomas F. Jr. - SC 13G/A Passive Investment SC 13G/A 1 d461700dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Titl |
|
| February 14, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / Anchorage Capital Group, L.L.C. - SC 13G/A Passive Investment SC 13G/A 1 brhc1004764413ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GINKGO BIOWORKS HOLDINGS, INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 37611X100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of t |
|
| February 14, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securitie |
|
| February 13, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / GENERAL ATLANTIC LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 eh23032893813ga2-ginkgo.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 37611X100 (CUSIP Number) December 31, 2022 (Date of Event which Requir |
|
| February 10, 2023 |
SC 13G/A 1 p23-0750sc13ga.htm GINKGO BIOWORKS HOLDINGS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 37611X100 (CUSIP Number) December 31, 2022 (Date of Event Whic |
|
| February 10, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Ginkgo Bioworks Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 37611X100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| February 3, 2023 |
GINKGO BIOWORKS HOLDINGS, INC. 7,279,426 Shares of Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-269443 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. 7,279,426 Shares of Class A Common Stock This prospectus relates to the resale or other disposition from time to time of up to 7,279,426 shares in the aggregate (the “Shares”) of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), of Ginkgo Bioworks H |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 27, 2023 Table of Contents As filed with the Securities and Exchange Commission on January 27, 2023 Registration No. |
|
| January 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| January 27, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial information and related notes have been prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma condensed combined balance sheet as of September 30, 2022 gives effect to the Merger (as defined below) as if the transaction ha |
|
| January 27, 2023 |
Exhibit 99.1 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) ZYMERGEN INC. Interim Periods Ended September 30, 2022 and September 30, 2021 Page Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders |
|
| January 27, 2023 |
EX-FILING FEES 6 d395334dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Ginkgo Bioworks Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxim |
|
| January 25, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / Shetty Reshma P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CUSIP Number) c/o Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue, 8th Floor Boston, MA 02210 (877) 422-5362 (Name, Address and Telep |
|
| January 25, 2023 |
DNA / Ginkgo Bioworks Holdings Inc / Kelly Jason R - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CUSIP Number) c/o Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue, 8th Floor Boston, MA 02210 (877) 422-5362 (Name, Address and Telep |
|
| January 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2023 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| January 11, 2023 |
Exhibit 99.1 Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs Year end cash balance of approximately $1.3 billion provides ample liquidity and puts Ginkgo in a position of strength to continue to build its leadership position despite a challenging macroenvironment Strong growth am |
|
| November 18, 2022 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following table sets forth the various expenses, other than any underwriting discounts and commissions, in connection with the sale and distribution of the securities being registered. Securities and Exchange Commission Registration Fee $ 55,100 FINRA Filing Fee $ 75,500 Printing an |
|
| November 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (C |
|
| November 18, 2022 |
Underwriting Agreement, dated November 15, 2022, by and between the Company and BTIG, LLC. Exhibit 1.1 Execution Version Ginkgo Bioworks Holdings, Inc. Class A Common Stock, par value $0.0001 per share Underwriting Agreement November 15, 2022 BTIG, LLC 65 E. 55th Street New York, New York 10022 Ladies and Gentlemen: Ginkgo Bioworks Holdings, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated in this agreement (this ?Agreement?), to issue a |
|
| November 17, 2022 |
41,383,877 Shares Ginkgo Bioworks Holdings, Inc. Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267743 Prospectus supplement (To prospectus dated October 14, 2022) 41,383,877 Shares Ginkgo Bioworks Holdings, Inc. Class A Common Stock We, Ginkgo Bioworks Holdings, Inc., are offering 41,383,877 shares of our Class A common stock, par value $0.0001 per share (?Class A common stock?). We intend to use the net proceeds of thi |
|
| November 15, 2022 |
Subject to completion, dated November 15, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267743 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to our common stock has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these secu |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2022 |
Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2022 Financial Results 15 new Cell Programs added and $66 million of Total revenue in Q3 2022 Closed four acquisitions in October, including Zymergen and Bayer?s West Sacramento agricultural biologicals capabilities, enabling commencement of integration and pursuit of new growth opportunities End of quarter cash balance of over $1.3 billion provid |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| October 19, 2022 |
EX-FILING FEES 8 d410784dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ginkgo Bioworks Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price |
|
| October 19, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 19, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Co |
|
| October 19, 2022 |
As filed with the United States Securities and Exchange Commission on October 19, 2022. As filed with the United States Securities and Exchange Commission on October 19, 2022. |
|
| October 19, 2022 |
Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan. Exhibit 4.6 GINKGO BIOWORKS HOLDINGS, INC. 2022 INDUCEMENT PLAN ARTICLE I. PURPOSE The Plan?s purpose is to allow the Company to provide an inducement to secure and retain the services of Eligible Individuals (as defined in Article II) by providing these individuals with equity ownership opportunities. Capitalized terms not otherwise defined in the Plan are defined in Article XI. ARTICLE II. ELIGI |
|
| October 19, 2022 |
Form of RSU Award Grant Notice (Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan). Exhibit 4.7 GINKGO BIOWORKS HOLDINGS, INC. 2022 INDUCEMENT PLAN GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Global Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Inducement Plan (as amended from time to time, the ?Plan?) of Ginkgo Bioworks Holdings, Inc. (the ?Company?). The Company has granted to |
|
| October 19, 2022 |
Ginkgo Bioworks Completes Acquisition of Zymergen Exhibit 99.1 Ginkgo Bioworks Completes Acquisition of Zymergen BOSTON, MA and EMERYVILLE, CA ? October 19, 2022 ? Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo?s platform by integratin |
|
| October 18, 2022 |
As filed with the Securities and Exchange Commission on October 18, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2022 Registration No. |
|
| October 18, 2022 |
As filed with the Securities and Exchange Commission on October 18, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2022 Registration No. |
|
| October 18, 2022 |
As filed with the Securities and Exchange Commission on October 18, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2022 Registration No. |
|
| October 18, 2022 |
As filed with the Securities and Exchange Commission on October 18, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2022 Registration No. |
|
| October 12, 2022 |
Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 October 12, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Ginkgo Bioworks Holdings, Inc. Registration Statement on Form S-3 (File No. 333-267743) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 |
|
| October 11, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| October 5, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / Kelly Jason R - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CUSIP Number) c/o Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue, 8th Floor Boston, MA 02210 (877) 422-5362 (Name, Address and Telep |
|
| October 5, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| October 5, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / Shetty Reshma P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CUSIP Number) c/o Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue, 8th Floor Boston, MA 02210 (877) 422-5362 (Name, Address and Telep |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 4, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 4, 2022 Registration No. |
|
| October 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| October 4, 2022 |
Exhibit 99.1 EXPLANATORY NOTE Ginkgo Bioworks Holdings, Inc. is filing this exhibit (this ?Exhibit?) to reflect changes to the presentation of its financial information as set forth in its Annual Report on Form 10-K for the year ended December 31, 2021 (the ?2021 Form 10-K?), as filed with the Securities and Exchange Commission on March 29, 2022. This Exhibit is being filed solely to present retro |
|
| September 29, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267315 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 3,178,887 Shares of Class A Common Stock of Ginkgo Bioworks Holdings, Inc. This prospectus relates to the resale from time to time by the selling securityholders named in this prospectus (which term as used in this prospectus includes their respective transferees, |
|
| September 27, 2022 |
As filed with the Securities and Exchange Commission on September 27, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 27, 2022 Registration No. |
|
| September 27, 2022 |
Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 September 27, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Re: Ginko Bioworks Holdings, Inc. Registration Statement on Form S-1 (File No. 333-267315) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule |
|
| September 22, 2022 |
ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM September 22, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Joe McCann Re: Ginkgo Bioworks Holdings, Inc. Registration Statement on Form S-1 Filed September 7, 2022 Fil |
|
| September 14, 2022 |
PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANT Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267241 PROXY STATEMENT OF ZYMERGEN INC. PROSPECTUS OF GINKGO BIOWORKS HOLDINGS, INC. PROPOSED MERGER?YOUR VOTE IS VERY IMPORTANT Dear Zymergen Stockholders: You are cordially invited to attend a special meeting of the stockholders of Zymergen Inc., a Delaware public benefit corporation (?Zymergen?), which will be held at 11:00 |
|
| September 13, 2022 |
S-4/A 1 d373595ds4a.htm FORM S-4/A Table of Contents As filed with the Securities and Exchange Commission on September 12, 2022 Registration No. 333-267241 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) De |
|
| September 13, 2022 |
Consent of Cowen and Company, LLC. Exhibit 99.1 COWEN AND COMPANY, LLC September 12, 2022 Board of Directors Zymergen Inc. 5959 Horton Street, Suite 700 Emeryville, CA 94608 Members of the Board: We hereby consent to the inclusion of our opinion letter, dated July 24, 2022, to the Board of Directors of Zymergen Inc. (?Zymergen?) as Annex E to, and to the reference thereto under the headings ?Summary ? Opinion of Financial Advisor t |
|
| September 13, 2022 |
Form of Proxy Card of Zymergen Inc. Exhibit 99.2 TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: ? KEEP THIS PORTION FOR YOUR RECORDS ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY The Board of Directors recommends you vote FOR proposals 1 and 2. For Against Abstain 1.???Adoption of the Agreem |
|
| September 12, 2022 |
September 12, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 9, 2022 |
GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-258712 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus or their permitted transferees (collectively, the ?Selling Stockholders?) of up to 77,500,000 shares of Class A common stock (th |
|
| September 9, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-261318 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 84,346,092 Shares of Class A Common Stock, 51,824,925 Shares of Class A Common Stock Underlying Warrants and 17,325,000 Private Placement Warrants of Ginkgo Bioworks Holdings, Inc. This prospectus relates to (i) the resale of 84,346,092 shares of our Class A commo |
|
| September 9, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264129 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 292,051,107 Shares of Class A Common Stock of Ginkgo Bioworks Holdings, Inc. This prospectus relates to the resale from time to time by the selling securityholders named in this prospectus (which term as used in this prospectus includes their respective transferee |
|
| September 7, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on September 7 , 2022 Registration No. |
|
| September 7, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| September 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| September 2, 2022 |
Powers of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on September 1, 2022 Registration No. |
|
| September 2, 2022 |
Consent of Cowen and Company LLC. Exhibit 99.1 COWEN AND COMPANY, LLC September 1, 2022 Board of Directors Zymergen Inc. 5959 Horton Street, Suite 700 Emeryville, CA 94608 Members of the Board: We hereby consent to the inclusion of our opinion letter, dated July 24, 2022, to the Board of Directors of Zymergen Inc. (?Zymergen?) as Annex E to, and to the reference thereto under the headings ?Summary ? Opinion of Financial Advisor to |
|
| September 2, 2022 |
Form of Proxy Card of Zymergen Inc. Exhibit 99.2 TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: ? KEEP THIS PORTION FOR YOUR RECORDS ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY The Board of Directors recommends you vote FOR proposals 1 and 2. For Against Abstain 1.???Adoption of the Agreem |
|
| September 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on September 1 , 2022 Registration No. |
|
| September 1, 2022 |
Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS ALLONNIA, LLC Audited consolidated financial statements for the years ended December 31, 2021 and 2020 Independent Auditors? Report F-1 Consolidated Financial Statements: Consolidated Balance Sheets as of December 31, 2021 and 2020 F-3 Consolidated Statements of Operations for the years ended December 31, 2021 and 2020 F-4 Consolidated Statements of Chang |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001- |
|
| September 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on August 31, 2022 Registration No. |
|
| September 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on August 31, 2022 Registration No. |
|
| August 16, 2022 |
424B3 1 d379840d424b3.htm 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-261318 Prospectus Supplement No. 4 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 84,346,092 Shares of Class A Common Stock, 51,824,925 Shares of Class A Common Stock Underlying Warrants and 17,325,000 Private Placement Warrants of Ginkgo Bioworks Ho |
|
| August 16, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001 – 40354 Date: August 16, 2022 The following are excerpts from the transcript for the earnings call held by Ginkgo Bioworks Holdings, Inc. for the quarter ended June 30 |
|
| August 16, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001 - 40354 Date: August 15, 2022 The following are slides from a presentation given by Ginkgo Bioworks Holdings, Inc. in connection with its earnings call for the quarter |
|
| August 16, 2022 |
GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-258712 Prospectus Supplement No. 4 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated March 31, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S |
|
| August 16, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-264129 Prospectus Supplement No. 3 (To Prospectus dated April 12, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 292,051,107 Shares of Class A Common Stock of Ginkgo Bioworks Holdings, Inc. This prospectus supplement updates, amends and supplements the prospectus dated April 12, 2022 (the ?Prospectus?), which fo |
|
| August 15, 2022 |
Exhibit 10.1 GINKGO BIOWORKS HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the ?Plan?) of Ginkgo Bioworks Holdings, Inc. (the ?Company?). The Company has granted to the participant list |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| August 15, 2022 |
Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2022 Financial Results $145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021 13 new Cell Programs added in Q2 2022, representing 86% growth over Q2 2021 Pending acquisitions of Zymergen and Bayer's West Sacramento agricultural biologicals capabilities expected to enable new growth opportunities in the coming years Approx |
|
| August 15, 2022 |
Exhibit 10.2 GINKGO BIOWORKS HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Global Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the ?Plan?) of Ginkgo Bioworks Holdings, Inc. (the ?Company?). The Company has |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Com |
|
| August 15, 2022 |
Exhibit 10.3 27 Drydock Avenue Boston, Massachusetts (the ?Building?) FOURTEENTH AMENDMENT (?FOURTEENTH AMENDMENT?) Execution Date: June 1, 2022 LANDLORD: BCP-CG 27 Property LLC, a Delaware limited liability company TENANT: Ginkgo Bioworks, Inc., a Delaware corporation EXISTING PREMISES: A total of 178,161 rentable square feet of the Building, as more specifically set forth in the Lease. DATE OF L |
|
| August 15, 2022 |
Exhibit 10.4 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Amendment?), is made as of the 10th day of August, 2022 (the ?Effective Date?), by and between IDB 21-25 DRYDOCK LIMITED PARTNERSHIP, a Delaware limited partnership (the ?Landlord?) and GINKGO BIOWORKS, INC., a Delaware corporation (the ?Tenant?). WITNESSETH: Reference is hereby made to the following facts: A. Landlord (a |
|
| August 4, 2022 |
GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock 424B3 1 d368973d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-258712 Prospectus Supplement No. 3 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated March 31, 2022 (the “Prospectus”), which forms a part of our Registration State |
|
| August 4, 2022 |
424B3 1 d384626d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-261318 Prospectus Supplement No. 3 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 84,346,092 Shares of Class A Common Stock, 51,824,925 Shares of Class A Common Stock Underlying Warrants and 17,325,000 Private Placement Warrants of Ginkgo Bioworks Holdings, Inc. This |
|
| August 4, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-264129 Prospectus Supplement No. 2 (To Prospectus dated April 12, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 292,051,107 Shares of Class A Common Stock of Ginkgo Bioworks Holdings, Inc. This prospectus supplement updates, amends and supplements the prospectus dated April 12, 2022 (the ?Prospectus?), which forms a part of our |
|
| August 4, 2022 |
Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors EX-99.1 2 dna-ex991.htm EX-99.1 Exhibit 99.1 Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors BOSTON, MA — August 4, 2022 — Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022. Dr. Hannan brings over thirty years of experience as a |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Comm |
|
| July 26, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001-40354 Date: July 25, 2022 On July 25, 2022, Ginkgo Bioworks Holdings, Inc. (?Ginkgo?) made available the following communications. * * * * * Email to customers Dear [c |
|
| July 26, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001-40354 Date: July 25, 2022 Blog post made available by Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) on July 25, 2022 at https://www.ginkgobioworks.com/2022/07/25/exciting- |
|
| July 25, 2022 |
Exhibit 10.1 Execution Version VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of July 24, 2022, is made and entered into by and between Ginkgo Bioworks Holdings, Inc., a Delaware corporation (?Parent?), and SVF Excalibur (Cayman) Limited (the ?Stockholder?), a stockholder of Zymergen Inc., a Delaware public benefit corporation (the ?Company?). Parent and Stockholder are someti |
|
| July 25, 2022 |
EX-99.1 2 d368669dex991.htm EX-99.1 Exhibit 99.1 Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities Ginkgo to acquire Bayer’s 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs BOSTON, MA, July 25, 2022–Ginkgo Bioworks (NYSE: DNA), the lead |
|
| July 25, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001-40354 Date: July 25, 2022 M&A Strategy Update Accelerating scale to better deliver for our customers July 25, 2022 Disclaimer Forward Looking Statements This communica |
|
| July 25, 2022 |
425 1 d368627d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdictio |
|
| July 25, 2022 |
Exhibit 10.3 Execution Version VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of July 24, 2022, is made and entered into by and among Ginkgo Bioworks Holdings, Inc., a Delaware corporation (?Parent?), and the stockholders of Zymergen Inc., a Delaware public benefit corporation (the ?Company?), identified on Exhibit A (each, a ?Stockholder? and collectively, the ?Stockholders?) |
|
| July 25, 2022 |
EX-2.1 2 d368627dex21.htm EX-2.1 Exhibit 2.1 Execution Version July 24, 2022 GINKGO BIOWORKS HOLDINGS, INC. PEPPER MERGER SUBSIDIARY INC. ZYMERGEN INC. AGREEMENT AND PLAN OF MERGER CONTENTS CLAUSE PAGE ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Index of Defined Terms 21 1.3 Certain Interpretations 23 ARTICLE II THE MERGER 25 2.1 The Merger 25 2.2 The Effective Time 25 |
|
| July 25, 2022 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2022 |
Exhibit 10.2 Execution Version VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of July 24, 2022, is made and entered into by and among Ginkgo Bioworks Holdings, Inc., a Delaware corporation (?Parent?), and the stockholders of Zymergen Inc., a Delaware public benefit corporation (the ?Company?), identified on Exhibit A (each, a ?Stockholder? and collectively, the ?Stockholders?) |
|
| July 25, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001-40354 Date: July 25, 2022 Transcript of the webcast ?M&A Strategy Update?, which was made available by Ginkgo Bioworks Holdings, Inc. on July 25, 2022 and can be acces |
|
| July 25, 2022 |
Exhibit 99.1 Ginkgo to Acquire Zymergen ? Acquisition is expected to accelerate the development of Ginkgo?s innovative horizontal synthetic biology platform ? Expect integration of Zymergen?s complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo?s platform for its diverse customer base a |
|
| July 25, 2022 |
Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001-40354 Date: July 25, 2022 On July 25, 2022, Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) made available the following communications. * * * * * Communication to Ginkgo Em |
|
| July 1, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 37611X100 (CUSIP |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commi |
|
| May 17, 2022 |
424B3 1 d291924d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-264129 Prospectus Supplement No. 1 (To Prospectus dated April 12, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 292,051,107 Shares of Class A Common Stock of Ginkgo Bioworks Holdings, Inc. This prospectus supplement updates, amends and supplements the prospectus dated April 12, 2022 (the “Prospect |
|
| May 17, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-261318 Prospectus Supplement No. 2 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 84,346,092 Shares of Class A Common Stock, 51,824,925 Shares of Class A Common Stock Underlying Warrants and 17,325,000 Private Placement Warrants of Ginkgo Bioworks Holdings, Inc. This prospectus supplement updates, a |
|
| May 17, 2022 |
GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock 424B3 1 d353887d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-258712 Prospectus Supplement No. 2 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated March 31, 2022 (the “Prospectus”), which forms a part of our Registration State |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. |
|
| May 16, 2022 |
Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2022 Financial Results $168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021 11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021 Increasing full year guidance for Total revenue from $325 ? $340 million to $375? $390 million, reiterating Foundry revenue guidance and increasing Biosecurity r |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commis |
|
| May 13, 2022 |
424B3 1 d299392d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-261318 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 84,346,092 Shares of Class A Common Stock, 51,824,925 Shares of Class A Common Stock Underlying Warrants and 17,325,000 Private Placement Warrants of Ginkgo Bioworks Holdings, Inc. This prospectus relates to (i) the resale of 84,346,092 shares of our |
|
| May 13, 2022 |
GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-258712 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus or their permitted transferees (collectively, the ?Selling Stockholders?) of up to 77,500,000 shares of Class A common stock (the ?PIPE Shares?), |
|
| May 13, 2022 |
424B3 1 d339994d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-264129 PROSPECTUS GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 292,051,107 Shares of Class A Common Stock of Ginkgo Bioworks Holdings, Inc. This prospectus relates to the resale from time to time by the selling securityholders named in this prospectus (which term as used in this prospectus includes their respect |
|
| April 29, 2022 |
Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 CORRESP 1 filename1.htm Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 April 29, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz Re: Ginkgo Bioworks Holdings, Inc. Registration Statement on Form S-1 (File No. 333-264129) Request for Acceleration Ladies and Gentlemen: Pu |
|
| April 28, 2022 |
DEFA14A 1 d352382ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 26, 2022 |
DEF 14A 1 d352792ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 12, 2022 |
424B3 1 d338615d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-261318 Prospectus Supplement No. 1 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. Prospectus for 84,346,092 Shares of Class A Common Stock, 51,824,925 Shares of Class A Common Stock Underlying Warrants and 17,325,000 Private Placement Warrants of Ginkgo Bioworks Holdings, Inc. This |
|
| April 12, 2022 |
S-1/A 1 d339994ds1a.htm S-1/A As filed with the Securities and Exchange Commission on April 12, 2022 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2836 87-2652913 (State or other jurisdic |
|
| April 12, 2022 |
GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-258712 Prospectus Supplement No. 1 (To Prospectus dated March 31, 2022) GINKGO BIOWORKS HOLDINGS, INC. 77,500,000 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated March 31, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration S |
|
| April 5, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on April 4, 2022 Registration No. |
|
| April 5, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Table S-1 (Form Type) Ginkgo Bioworks Holdings, Inc. |
|
| March 31, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 31, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 29, 2022 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary of the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Charter, our Bylaws and the Warrant-related documents described herein, which are filed with the Securities and Exchange Commission (the ?SEC?). We urge you to read e |
|
| March 29, 2022 |
Exhibit 4.4 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this ?Agreement?) is entered into as of September 16, 2021 by and among (i) Ginkgo Bioworks Holdings, Inc., a Delaware corporation (the ?Company?), (ii) Continental Stock Transfer & Trust Company, a New York corporation (?Continental?), and (iii) Computershare Trust Company, N.A., a federally chartered trust |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| March 28, 2022 |
Exhibit 99.1 Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results $314 million of Total revenue in 2021, representing an increase of 309% over 2020 31 new Cell Programs added in 2021, representing 72% growth over 2020 Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability BOSTON, MA - March 28, 2022 - Ginkgo Bioworks Holdings |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Comm |
|
| March 4, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / VIKING GLOBAL INVESTORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 37611X100 (CUSIP Number) Andrew Genser General Counsel 55 Railroad Avenue Greenwich, Connecticut 06830 203-863-7050 (Name, Ad |
|
| February 15, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / Che Austin - SC 13G/A Passive Investment SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 3761 |
|
| February 15, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / Knight Thomas F. Jr. - SC 13G/A Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 37611X100 (CU |
|
| February 14, 2022 |
DNA / Ginkgo Bioworks Holdings Inc / Anchorage Capital Group, L.L.C. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GINKGO BIOWORKS HOLDINGS, INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 37611X100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2022 |
SC 13G/A 1 tm224549d21sc13ga.htm GINKGO BIOWORKS HOLDINGS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Ginkgo Bioworks Holdings, Inc. (Name of Issuer) Class A common stock, par v |
